TBPH Stock — Theravance Biopharma Inc.: Cash, EV, Pipeline

Share price

$17.02

Market cap

$883.7M

Cash

$387.7M

Enterprise value

$496.0M

Balance sheet

Cash	$387.7M
Debt	$0.0M
Net cash	$387.7M
Enterprise value	$496.0M
Basic shares	51.9M shares
Fully diluted shares	64.0M shares
Fully diluted market cap	$1,089.0M
Cash per share	$7.47

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TBPH daily closes…

Loading price history…

Pipeline assets

YUPELRI

Approved · Active Modality: once-daily nebulized long-acting muscarinic antagonist (LAMA)

Target muscarinic receptor (LAMA)

Partnerships Viatris: strategic collaboration (2015) for development/commercialization of revefenacin; Viatris holds exclusive rights in China and adjacent territories (Hong Kong SAR, Macau SAR, Taiwan)

Indications

COPD (maintenance treatment) (Approved)

Status note Revefenacin inhalation solution, FDA-approved for maintenance treatment of COPD in the US.

Ampreloxetine

Phase 3 · Terminated Modality: small molecule (oral, once-daily)

Target NET

Partnerships Royalty Pharma: contingent funding in exchange for future royalty rights

Indications

symptomatic neurogenic orthostatic hypotension in multiple system atrophy (CYPRESS) (Phase 3)

Status note Once-daily norepinephrine reuptake inhibitor for nOH in MSA. SEQUOIA (2021) and REDWOOD (2022) Phase 3 studies missed their primary endpoints; CYPRESS Phase 3 topline (March 3, 2026) missed its primary endpoint, and the company decided to wind down the ampreloxetine program.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07816835	Not disclosed	Recruiting	Collaborator	COPD Foundation	—	COPD (Chronic Obstructive Pulmonary Disease); Chronic Obstructive Pulmonary Disease (COPD)	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for COPD Foundation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

TBPH — Theravance Biopharma Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials